BRPI0514544A - ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1) - Google Patents

ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)

Info

Publication number
BRPI0514544A
BRPI0514544A BRPI0514544-9A BRPI0514544A BRPI0514544A BR PI0514544 A BRPI0514544 A BR PI0514544A BR PI0514544 A BRPI0514544 A BR PI0514544A BR PI0514544 A BRPI0514544 A BR PI0514544A
Authority
BR
Brazil
Prior art keywords
pai
oxazol
modulators
plasminogen activator
activator inhibitor
Prior art date
Application number
BRPI0514544-9A
Other languages
English (en)
Inventor
Thomas Joseph Commons
Jr Richard Page Woodworth
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0514544A publication Critical patent/BRPI0514544A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

CIDOS DE OXAZOL-NAFTILA COMO MODULADORES DE INIBIDOR TIPO-1 DE ATIVADOR DE PLASMINOGêNIO (PAI-1). A presente invenção refere-se aos ácidos oxazol-naftila da fórmula (I) e métodos de empregá-los para modular a expressão de PAI-1 e para tratar distúrbios relacionados com PAI-1.
BRPI0514544-9A 2004-08-23 2005-08-22 ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1) BRPI0514544A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60373604P 2004-08-23 2004-08-23
PCT/US2005/029823 WO2006023865A1 (en) 2004-08-23 2005-08-22 Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases

Publications (1)

Publication Number Publication Date
BRPI0514544A true BRPI0514544A (pt) 2008-06-17

Family

ID=35431452

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514544-9A BRPI0514544A (pt) 2004-08-23 2005-08-22 ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)

Country Status (16)

Country Link
US (1) US7754747B2 (pt)
EP (1) EP1781645A1 (pt)
JP (1) JP2008510815A (pt)
KR (1) KR20070055563A (pt)
CN (1) CN101039936A (pt)
AU (1) AU2005277138A1 (pt)
BR (1) BRPI0514544A (pt)
CA (1) CA2577857A1 (pt)
CR (1) CR8930A (pt)
EC (1) ECSP077269A (pt)
IL (1) IL181331A0 (pt)
MX (1) MX2007002178A (pt)
NO (1) NO20071379L (pt)
RU (1) RU2007106868A (pt)
WO (1) WO2006023865A1 (pt)
ZA (1) ZA200701582B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052855A2 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
US7534894B2 (en) * 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7411083B2 (en) * 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
RU2007106869A (ru) * 2004-08-23 2008-09-27 Вайет (Us) Тиазол-нафтиловые кислоты как ингибиторы ингибитора активации плазминогена-1
WO2006023864A1 (en) * 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
BRPI0614340A2 (pt) * 2005-08-17 2011-04-12 Wyeth Corp indóis substituìdos e métodos de seu uso
RU2008128475A (ru) * 2006-02-27 2010-04-10 Вайет (Us) Ингибиторы pai-1 для лечения состояний мышечной системы
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
RU2018100142A (ru) 2010-03-24 2019-02-20 Амитек Терапетикс Солюшинс, Инк. Гетероциклические соединения, эффективные для ингибирования киназы
CN106890324A (zh) * 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
CN108778307A (zh) 2015-12-18 2018-11-09 泰伦基国际有限公司 一种预防和治疗糖尿病肾病的方法
US20190314464A1 (en) 2016-12-15 2019-10-17 Talengen International Limited Novel method for treating diabetes
EP4171527A1 (en) 2020-06-25 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment and diagnostic of pathological conditions associated with intense stress

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3026325A (en) * 1959-01-26 1962-03-20 Upjohn Co 5-hydroxy-alpha-alkyltryptophans
US3476770A (en) * 1967-04-14 1969-11-04 Parke Davis & Co 2-methyl-7-phenylindole-3-acetic acid compounds
GB1321433A (en) 1968-01-11 1973-06-27 Roussel Uclaf 1,2,3,6-tetrasubstituted indoles
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
FR2244499A1 (en) 1973-06-07 1975-04-18 Delalande Sa Indol-3-ylformaldoxime carbamates - for treating anxiety epilepsy, cardiac arrhythmias, asthma, intestinal spasm, peptic ulcer, cardiac insufficiency
DE3147276A1 (de) * 1981-11-28 1983-06-09 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von indolderivaten, deren verwendung als wertvolle zwischenprodukte und neue 4-hydroxyindole
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
DE3531658A1 (de) * 1985-09-05 1987-03-12 Boehringer Mannheim Gmbh Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel
JPS63139172A (ja) 1986-12-02 1988-06-10 Morishita Seiyaku Kk ４，５−ジヒドロ−６−（６−置換−２−ナフチル）−３（２ｈ）−ピリダジノン誘導体
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US5164372A (en) * 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
WO1991000277A1 (en) 1989-06-30 1991-01-10 E.I. Du Pont De Nemours And Company Substituted imidazoles
IE903206A1 (en) 1989-09-07 1991-03-13 Abbott Lab Indole-, benzofuran-, and benzothiophene-containing¹lipoxygenase-inhibiting compounds
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
US5234917A (en) * 1989-12-29 1993-08-10 Finkelstein Joseph A Substituted 5-(alkyl)carboxamide imidazoles
CA2037630C (en) 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DE4035961A1 (de) * 1990-11-02 1992-05-07 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5187179A (en) 1991-03-22 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted imidazo [1,2-b][1,2,4]triazole
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
US5198438A (en) 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
IL101785A0 (en) 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
DE59209008D1 (de) * 1991-08-17 1997-12-11 Hoechst Ag 2-Fluorpyrazine, Verfahren zu ihrer Herstellung und ihre Verwendung in flüssigkristallinen Mischungen
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
GB9124578D0 (en) 1991-11-20 1992-01-08 Smithkline Beecham Plc Chemical compounds
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
GB9213934D0 (en) 1992-06-30 1992-08-12 Smithkline Beecham Corp Chemical compounds
DE4242675A1 (de) 1992-12-17 1994-06-23 Basf Ag Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
IL109568A0 (en) 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6137002A (en) * 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
CA2134192A1 (en) 1993-11-12 1995-05-13 Michael L. Denney 5, 6-bicyclic glycoprotein iib/iiia antagonists
DE4341453A1 (de) 1993-12-06 1995-06-08 Merck Patent Gmbh Imidazopyridine
DE4341665A1 (de) * 1993-12-07 1995-06-08 Basf Ag Bicyclen-Derivate, ihre Herstellung und Verwendung
FR2713640B1 (fr) 1993-12-15 1996-01-05 Cird Galderma Nouveaux composés aromatiques polycycliques, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
DE69529690T2 (de) 1994-12-21 2003-11-13 Merck Frosst Canada Inc Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
DE69622031T2 (de) 1995-04-10 2002-12-12 Fujisawa Pharmaceutical Co INDOLDERIVATE ALS cGMP-PDE INHIBITOREN
FR2733684B1 (fr) 1995-05-03 1997-05-30 Cird Galderma Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
WO1997004774A1 (en) 1995-08-02 1997-02-13 Smithkline Beecham Corporation Endothelin receptor antagonists
US5728724A (en) 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
IL120724A0 (en) 1995-09-01 1997-08-14 Lilly Co Eli Indolyl neuropeptide Y receptor antagonists
DE19537548A1 (de) 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19543639A1 (de) 1995-11-23 1997-05-28 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
EP0925297A1 (en) 1996-02-01 1999-06-30 Smithkline Beecham Corporation Endothelin receptor antagonists
GB9609641D0 (en) 1996-05-09 1996-07-10 Pfizer Ltd Compounds useful in therapy
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
CA2207083A1 (en) 1996-07-15 1998-01-15 Brian William Grinnell Benzothiophene compounds, and uses and formulations thereof
US5859044A (en) * 1996-07-31 1999-01-12 Pfizer Inc. β-adrenergic agonists
WO1998008818A1 (en) 1996-08-26 1998-03-05 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
JP3409029B2 (ja) 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害剤としてのアリールチオフェン誘導体
DE19753522A1 (de) 1997-12-03 1999-06-10 Boehringer Ingelheim Pharma Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel
AU2782699A (en) 1998-02-25 1999-09-15 Genetics Institute, Llc Inhibitors of phospholipase enzymes
PL343007A1 (en) 1998-02-25 2001-07-30 Genetics Inst Inhibitors of phospholipase enzymes
EE200000522A (et) 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
SE9800836D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
FR2777886B1 (fr) 1998-04-27 2002-05-31 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6110963A (en) * 1998-05-12 2000-08-29 American Home Products Corporation Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6166069A (en) * 1998-05-12 2000-12-26 American Home Products Corporation Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6232322B1 (en) * 1998-05-12 2001-05-15 American Home Products Corporation Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6251936B1 (en) * 1998-05-12 2001-06-26 American Home Products Corporation Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
CA2331120A1 (en) 1998-05-12 1999-11-18 Iwan Gunawan Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
IL139132A0 (en) 1998-05-12 2001-11-25 American Home Prod Benzothiophenes, benzofurans and indoles useful in the treatment of insulin resistance and hyperglycemia
CA2331118A1 (en) 1998-05-12 1999-11-18 Wyeth Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
JP2002525371A (ja) 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
JP2002275157A (ja) 1998-11-20 2002-09-25 Torii Yakuhin Kk 新規ナフタレン誘導体
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
EP1140802B1 (de) * 1998-12-16 2004-03-17 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte aryl- und heteroarylamidinderivate, deren herstellung und deren verwendung als arzneimittel
AU2319100A (en) 1999-01-28 2000-08-18 Nippon Shinyaku Co. Ltd. Amide derivatives and drug compositions
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
BR0010126A (pt) 1999-04-28 2002-02-26 Aventis Pharma Gmbh Derivados de ácido tri-arìlico como ligandos receptores de ppar
ATE368037T1 (de) 1999-04-28 2007-08-15 Sanofi Aventis Deutschland Di-aryl-säurederivate als ppar rezeptor liganden
WO2001077076A1 (fr) 1999-06-02 2001-10-18 Torii Pharmaceutical Co., Ltd. Nouveaux derives de naphtalene
GB9919413D0 (en) * 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
FR2799756B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19963178A1 (de) * 1999-12-27 2001-07-05 Gruenenthal Gmbh Substituierte Indol-Mannichbasen
AU2001236471A1 (en) 2000-01-18 2001-07-31 Neurogen Corporation Imidazopyridines and related azacyclic derivatives as selective modulators of bradykinin b2 receptors
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CA2427499A1 (en) 2000-10-10 2002-04-18 Smithkline Beecham Corporation Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents
AUPR118000A0 (en) 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
FR2825706B1 (fr) 2001-06-06 2003-12-12 Pf Medicament Nouveaux derives de benzothienyle ou d'indole, leur preparation et leur utilisation comme inhibiteurs de proteines prenyl transferase
US7291639B2 (en) * 2001-06-20 2007-11-06 Wyeth Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
ATE367812T1 (de) 2001-06-20 2007-08-15 Wyeth Corp Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1)
TW591020B (en) 2001-06-20 2004-06-11 Wyeth Corp 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) * 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
KR100810468B1 (ko) * 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체
CN1642910A (zh) 2002-02-12 2005-07-20 威斯康星校友研究基金会 用于ah受体作为配体的吲哚噻唑化合物的合成
AU2003224257A1 (en) 2002-04-09 2003-10-27 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
AU2002368133A1 (en) 2002-07-29 2004-02-16 Shizuoka Coffein Co., Ltd. 1,3-azole derivative and medicinal composition containing the derivative for treatment for thombosis
CN1726191A (zh) * 2002-12-10 2006-01-25 惠氏公司 用作纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代的吲哚氧代－乙酰氨基乙酸衍生物
JP2006510673A (ja) 2002-12-10 2006-03-30 ワイス プラスミノゲンアクティベータインヒビター１（ｐａｉ−１）のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換１ｈ−インドール−３−イルグリオキシル酸誘導体
ES2268480T3 (es) * 2002-12-10 2007-03-16 Wyeth Derivados del acido 3-alquilo- y 3-arilalquilo-1h-indol-1-il-acetico sustituidos como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
WO2004052855A2 (en) * 2002-12-10 2004-06-24 Wyeth Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP4390460B2 (ja) * 2003-02-21 2009-12-24 株式会社静岡カフェイン工業所 オキサゾール誘導体
JP4330353B2 (ja) 2003-02-21 2009-09-16 株式会社静岡カフェイン工業所 ピリミジン誘導体
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US20050215626A1 (en) * 2003-09-25 2005-09-29 Wyeth Substituted benzofuran oximes
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles

Also Published As

Publication number Publication date
CR8930A (es) 2007-08-28
MX2007002178A (es) 2007-04-02
CA2577857A1 (en) 2006-03-02
JP2008510815A (ja) 2008-04-10
KR20070055563A (ko) 2007-05-30
ZA200701582B (en) 2009-09-30
US20060052348A1 (en) 2006-03-09
RU2007106868A (ru) 2008-09-27
ECSP077269A (es) 2007-03-29
AU2005277138A1 (en) 2006-03-02
WO2006023865A1 (en) 2006-03-02
US7754747B2 (en) 2010-07-13
IL181331A0 (en) 2007-07-04
CN101039936A (zh) 2007-09-19
NO20071379L (no) 2007-04-16
EP1781645A1 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
BRPI0514544A (pt) ácidos de oxazol-naftila como moduladores de inibidor tipo-1 de ativador de plasminogênio (pai-1)
BRPI0514549A (pt) ácidos de pirrol-naftila como inibidores de pai-1
ECSP077270A (es) Ácidos de tiazolo - naftilo
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
TW200745109A (en) Pyrrolo-pyridine kinase modulators
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
BRPI0517435A (pt) triazóis úteis como inibidores de proteìna cinase
HN2007000267A (es) Compuestos de 4-metil piridopirimidinoma
BRPI0413582A (pt) compostos, composições e métodos para inibir a atividade de proteasome
CR20110016A (es) Compuestos quimicos 251
HRP20050041B1 (hr) UPOTREBA INHIBITORA IκB KINAZE U TERAPIJI BOLOVA
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
CR10213A (es) Moduladores de la proteína quinasa aurora
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
NI200800290A (es) Moduladores bencimidazólicos de vr1
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
UY30918A1 (es) Moduladores de lta4h y sus usos
ATE448189T1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
ATE529742T1 (de) Siva-ubiquitinierung und/oder -abbau verbundene aktivität und modulatoren davon
UY39670A (es) Compuestos que tienen tetrahidroindolizina-1-carboxamida como inhibidores de bcl-2
ATE500731T1 (de) Biofilmsteuerung
UY30661A1 (es) Moduladores de proteina quinasa de triazalopiridazina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.